Based on a board resolution, 216,600 shares of common stock were acquired. Total acquisition amount was 290,532,700 yen. Acquisition period was 2026\/10\/15\u20132026\/10\/31, acquisition method was market purchase. The upper limit was planned at 1,250,000 shares (4.4% of issued shares), but the current cumulative total is 216,600 shares, totaling 290,532,700 yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4577","jir_company_name":"Daito Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4577-20261102-01.pdf","jir_short_summary":"Based on a board resolution, 216,600 shares of common stock were acquired. Total acquisition amount was 290,532,700 yen. Acquisition period was 2026\/10\/15\u20132026\/10\/31, acquisition method was market purchase. The upper limit was planned at 1,250,000 shares (4.4% of issued shares), but the current cumulative total is 216,600 shares, totaling 290,532,700 yen.","jir_summary":"### Overview of Treasury Stock Acquisition\nThe Company has been acquiring treasury stock of common shares in accordance with the Companies Act and the provisions of the Articles of Incorporation. On this occasion, the number of shares acquired was 216,600 shares, the total acquisition amount was 290,532,700 yen, the acquisition period was from October 15, 2026 to October 31, 2026, and the acquisition method was market purchase on the Tokyo Stock Exchange. At the board of directors meeting held on October 14, 2026, an upper limit of 1,250,000 shares (4.4% of the total number of issued shares) was assumed. The cumulative total at this time is 216,600 shares, totaling 290,532,700 yen.\n\n### Impact on Shareholders and Outlook\nThis acquisition was carried out by market purchases of treasury stock, and it is necessary to consider effects on dilution and on the share price. The upper limit is set at 1,250,000 shares, and the current cumulative total represents only a portion of that limit; therefore, the scope of future acquisitions and whether additional acquisitions will occur depend on publicly disclosed information. The acquisition period was completed within a short period of several weeks.","jir_financial_highlights":"Shares Acquired: 216,600 shares (Cumulative against upper limit of 1,250,000 shares (4.4%))\nTotal Acquisition Amount: 290,532,700 yen\nAcquisition Period: October 15, 2026 to October 31, 2026","jir_category":"","jir_hashtags":"#DaitoPharmaceuticalCoLtd_DietStockBuyback, #TreasuryStockAcquisitionNotice","jir_key_figures":"Shares Acquired: 216,600 shares (cumulative)\nTotal Acquisition Amount: 290,532,700 yen\nUpper Limit of Shares: 1,250,000 shares (upper limit)","jir_meta_title":"Daito Pharmaceutical Co., Ltd. - Notice of Treasury Stock Acquisition Status | November 02, 2026","jir_meta_description":"Daito Pharmaceutical Co., Ltd. announced the status of its treasury stock acquisition. Details include the number of shares acquired, total amount, and acquisition period, along with key points on potential additional acquisitions and shareholder impact.","jir_og_title":"Daito Pharmaceutical Co., Ltd. - Notice of Treasury Stock Acquisition Status | November 02, 2026","jir_og_description":"Daito Pharmaceutical Co., Ltd. acquired 216,600 shares of treasury stock for a total of 290,532,700 yen. The period was 10\/15\u201310\/31 and the method was market purchase. The upper limit was 1,250,000 shares (4.4%).","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56861,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-140087","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n